Darzalex (daratumumab)

Darzalex (daratumumab) is a targeted cancer therapy used to treat multiple myeloma, a type of blood cancer. It is a monoclonal antibody that specifically binds to a protein called CD38 on the surface of myeloma cells. By attaching to CD38, Darzalex helps the immune system recognize and destroy the cancer cells more effectively. It is usually given in combination with other treatments and administered through an intravenous infusion. Darzalex has improved outcomes for many patients by slowing disease progression and increasing survival rates.